NCT02512068View on ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

August 7, 2015

Primary Completion Date

April 24, 2018

Study Completion Date

April 24, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Trelagliptin 25 mg

Trelagliptin 25 mg Tablets

DRUG

Placebo

Placebo Tablets

Trial Locations (49)

Unknown

Anjo

Kasukabe

Nagoya

Toyohashi

Yatomi

Asahi

Kisarazu

Yotsukaidō

Imabari

Matsuyama

Niihama

Chikushino-shi

Kasuga

Kasuya-gun

Kitakyushu

Munakata

Tajimi

Takasaki

Fukuyama

Chitose

Himeji

Takarazuka

Mito

Sakai

Fujisawa

Kamakura

Kawasaki

Yokohama

Sendai

Nakano

Ueda

Kasaoka

Setouchi

Fukaya

Kumagaya

Hamamatsu

Yoshinogawa

Hachiōji

Itabashi-ku

Kunitachi

Uozu

Shimonoseki

Ube

Akita

Kumamoto

Nagano

Niigata

Osaka

Yamagata

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY